Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oculus Innovative Sciences has announced a regulatory approval in Mexico for the company's new Microcyn60 Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections.
Subscribe to our email newsletter
Oculus executive vice president Bruce Thornton noted this is an extremely exciting time for the company since it’s the first Microcyn-based product approved anywhere in the world for the antiseptic treatment of both mouth and throat infections.
"The commercialization of our Microcyn Technology for this promising new indication lays the foundation for its introduction into other international markets, in particular Europe. As we did with our recent Mexican approval of Microcyn for acne, we will leverage this Mexican approval for oral care by using the approved dossier in our submission to the European notified body for CE Mark approval.
"This two-step approach to regulatory submissions provides us the opportunity to migrate these new products to Europe in the quickest time possible," Thornton
The first oral care product to be launched by Oculus’ Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo. The More Pharma sales team intends to target general practitioners as well as ear, nose and throat specialists in mid-2014, enlightening these healthcare professionals to the advantages of Microdacyn60 Bucofaringeo well in advance of the 2014 fall/winter cold and flu season.